Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ulimorelin - Lyric Pharmaceuticals

Drug Profile

Ulimorelin - Lyric Pharmaceuticals

Alternative Names: LP 101; TZP-101; Ulimorelin hydrochloride

Latest Information Update: 14 Mar 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tranzyme
  • Developer Lyric Pharmaceuticals; Norgine; Tranzyme Pharma
  • Class Macrocyclic compounds; Small molecules
  • Mechanism of Action Ghrelin agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Nutrition disorders
  • Discontinued Cachexia; Digestive system disorders; Gastroparesis; Postoperative ileus

Most Recent Events

  • 05 Mar 2018 Lyric Pharmaceuticals completes enrolment in the phase II PROMOTE trial for Nutrition disorders in USA, Canada, Spain and Netherlands (IV)
  • 01 Mar 2018 Lyric Pharmaceuticals completes the phase II PROMOTE trial in Nutritional disorders (In patients with enteral feeding tolerance) in USA, Netherlands, Canada and Spain (NCT02784392)
  • 23 Jan 2018 Adverse events data from the phase II trial in Nutritional disorders released by Lyric Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top